國立科技(300716.SZ):控股子公司國立通盈擬與迪士尼簽署許可協議
格隆匯3月30日丨國立科技(300716.SZ)公佈,2020年3月30日,公司第二屆董事會第十八次會議審議通過了《關於控股子公司簽署許可協議的議案》,公司控股子公司廣東國立通盈科技發展有限公司(“國立通盈”、“被許可方”)擬與華特迪士尼(中國)有限公司(“迪士尼”)簽訂《許可協議》,許可國立通盈未來3年內在特定產品上使用相關迪士尼及漫威原型,並授權國立通盈通過指定的經銷渠道銷售許可產品。
此次國立通盈與迪士尼簽署許可協議,將公司產業鏈拓展至終端品牌運營,有利於公司擴大終端產品的銷售規模,提升銷售業績;有利於公司形成新的利潤增長點,提高公司的整體競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.